Characterization of ARF-BP1/HUWE1 Interactions with CTCF, MYC, ARF and p53 in MYC-Driven B Cell Neoplasms by Qi, Chen-Feng et al.
Int. J. Mol. Sci. 2012, 13, 6204-6219; doi:10.3390/ijms13056204 
 





Characterization of ARF-BP1/HUWE1 Interactions with CTCF, 
MYC, ARF and p53 in MYC-Driven B Cell Neoplasms 
Chen-Feng Qi 
1,*, Yong-Soo Kim 
1, Shao Xiang 
1,2, Ziedulla Abdullaev 
1, Ted A. Torrey 
3, 
Siegfried Janz 
4, Alexander L. Kovalchuk 
1, Jiafang Sun 
1, Delin Chen 
5, William C. Cho 
6,  
Wei Gu 
5 and Herbert C. Morse III 
1,* 
1  Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National 
Institutes of Health, Rockville, MD 20852, USA; E-Mails: kimyongs@mail.nih.gov (Y.-S.K.); 
xiangshao@gmail.com (S.X.); zabdul@mail.nih.gov (Z.A.); kovalcha@niaid.nih.gov (A.L.K.); 
sunj7@mail.nih.gov (J.S.) 
2  Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA 
3  Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases,  
National Institutes of Health, Bethesda, MD 20892, USA; E-Mail: ttorrey@niaid.nih.gov 
4  Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, 
USA; E-Mail: siegfried-janz@uiowa.edu 
5  Institute for Cancer Genetics, and Department of Pathology and Cell Biology, College of Physicians 
& Surgeons, Columbia University, New York, NY 10032, USA; E-Mails: dc723@columbia.edu 
(D.C.); wg8@columbia.edu (W.G.) 
6  Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China;  
E-Mail: chocs@ha.org.hk 
*  Authors to whom correspondence should be addressed; E-Mails: cqi@niaid.nih.gov (C.-F.Q.); 
hmorse@niaid.nih.gov (H.C.M.); Tel.: +1-301-402-2698 (C.-F.Q.); +1-301-496-6379 (H.C.M.); 
Fax: +1-301-402-0077 (H.C.M.; C.-F.Q.). 
Received: 22 March 2012; in revised form: 24 April 2012 / Accepted: 9 May 2012 /  
Published: 21 May 2012 
 
Abstract:  Transcriptional  activation  of  MYC  is  a  hallmark  of  many  B  cell  lineage 
neoplasms.  MYC  provides  a  constitutive  proliferative  signal  but  can  also  initiate  
ARF-dependent  activation  of  p53  and  apoptosis.  The  E3  ubiquitin  ligase,  ARF-BP1, 
encoded by HUWE1, modulates the activity of both the MYC and the ARF-p53 signaling 
pathways, prompting us to determine if it is involved in the pathogenesis of MYC-driven B 
cell lymphomas. ARF-BP1 was expressed at high levels in cell lines from lymphomas with 
either  wild  type  or  mutated  p53  but  not  in  ARF-deficient  cells.  Downregulation  of  
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ARF-BP1  resulted  in  elevated  steady  state  levels  of  p53,  growth  arrest  and  apoptosis.  
Co-immunoprecipitation studies identified a multiprotein complex comprised of ARF-BP1, 
ARF, p53, MYC and the multifunctional DNA-binding factor, CTCF, which is involved in 
the transcriptional regulation of MYC, p53 and ARF. ARF-BP1 bound and ubiquitylated 
CTCF leading to its proteasomal degradation. ARF-BP1 and CTCF thus appear to be key 
cofactors linking the MYC proliferative and p53-ARF apoptotic pathways.  In addition, 
ARF-BP1 could be a therapeutic target for MYC-driven B lineage neoplasms, even if p53 
is inactive, with inhibition reducing the transcriptional activity of MYC for its target genes 
and stabilizing the apoptosis-promoting activities of p53. 
Keywords: ARF-BP1; B-cell lymphoma; p53; MYC; CTCF; ARF 
 
1. Introduction 
Human  Burkitt  lymphoma  (BL)  is  characterized  in  most  cases  by  reciprocal  chromosomal 
translocations that juxtapose the MYC proto-oncogene with immunoglobulin (Ig) heavy chain or light 
chain regulatory sequences resulting in deregulation of MYC transcription [1]. Since MYC is critically 
involved in both G0→G1 cell cycle entry and cell cycle progression, both mRNA and protein levels 
must be tightly regulated to prevent abnormal cell growth. Normally, both MYC mRNA and protein 
exhibit rapid turnover with protein instability manifested by a half-life of less than 30 min [2]. Increased 
levels of MYC protein are reported in many cancers and have, in some instances, been associated with 
extended  half-lives  for  BL  and  pediatric  lymphoblastic  lymphoma  (LL) [2,3].  High  levels  of  MYC 
protein in cancers may thus reflect impairment of degradation pathways as well as increased transcription. 
MYC stability and transcriptional activity are both affected by multiple posttranslational modifications 
including phosphorylation, acetylation and ubiquitylation that serve to integrate the input from multiple 
signaling cascades. At least four different E3 ligase complexes contribute to MYC ubiquitylation and 
proteasome-mediated degradation: SKP2, FBW7 [4–7], ARF-BP1/HUWE1/HECT9 [8], and the recently 
described TRUSS-DDB1-CULA complex [9]. In each instance, overexpression of a dominant negative 
form, knockdown or gene deletion led to decreased MYC turnover. A comprehensive model for how 
the  activity  of  these  complexes  is  assimilated  to  direct  MYC  transcriptional  activity  and  protein 
stability in different types of normal cells or in cancers, including MYC-associated human BL and 
mouse MYC-driven lymphomas, has not been developed. Information on the features of each of these 
complexes has nonetheless been accumulating at an accelerated rate. 
Recent studies showed that SKP2 is expressed at high levels in most BL as well as lymphomas of 
Eµ-MYC transgenic (TG) mice [10,11]. The mouse lymphomas are phenotypically similar to normal 
immature  or  transitional  B  cells  and  together  with  tumors  of  λ-MYC  TG  mice [12]  have  been 
classified as diffuse high-grade blastic B cell lymphoma/leukemia (DBLL) [13]. Increased expression 
of SKP2 in DBLL was shown to be MYC-dependent but indirect, involving transcriptional as well as 
posttranslational mechanisms [10]. SKP2 interacts with MYC at promoters, acting as a co-factor for 
transcriptional activation, but subsequently mediates polyubiquitylation and proteasomal degradation. Int. J. Mol. Sci. 2012, 13  6206 
 
 
The  action  of  FBW7  on  MYC  requires  prior  phosphorylation  at  Ser-62  as  a  prerequisite  for  
GSK3-dependent  phosphorylation  at  Thr-58.  FBW7,  recruited  to  MYC  phosphorylated  at  Thr-58, 
polyubiquitylates  MYC,  branching  through  Lys-48,  and  leading  to  its  proteasomal  degradation. 
Although FBW7 has been considered as the primary determinant of MYC degradation, the finding that 
MYC protein levels are not enhanced by expression of stable Thr-58 mutants is inconsistent with this 
conclusion [14]. The potential contributions of FBW7 downregulation to the development of BL have 
not been explored. 
The TRUSS-DDB1-CUL4 E3 ligase complex targets both MYC and MYCN for ubiquitylation and 
proteasomal degradation independent of MYC phosphorylation on Thr-58 [9]. TRUSS expression is 
reduced in tumor cells, suggesting that downregulation may promote tumor formation by enhancing 
MYC protein stability. However, the previous tumor survey did not include hematopoietic neoplasms 
and, more specifically, BL. 
The transcriptional activity of MYC is enhanced by recruitment of the histone acetyl transferases 
(HATs) CBP/p300 to gene promoters. Subsequent binding of ARF-BP1 results in polyubiquitylation 
with  Lys-63  branching  which  does  not  lead  to  degradation  but  lead  to  enhanced  interaction  with 
CBP/p300 and stimulation of MYC acetylation. ARF-BP1 has also been shown to ubiquitylate p53, 
thereby promoting its degradation [14–16]. These activities of ARF-BP1 are inhibited by binding to 
ARF [17]. Again, the potential role of ARF-BP1 in modulating MYC-activated pathways in B cell 
lymphomagenesis has not been investigated. 
The current studies were undertaken to better understand the complex dynamics of ARF-BP1 and 
its partner proteins and targets in the transformation of B lineage cells by MYC, utilizing BL cell lines 
and cell lines derived from DBLL of MYC TG mice. Our study aims to support the hypothesis that by 
regulating MYC and p53 transcriptional activity, ARF-BP1 is a critical determinant of the proliferation 
of B cell lymphomas and suggest that interference with ARF-BP1 provides a potential strategy to 
inhibit MYC activity in these tumors. 
2. Results 
2.1. ARF-BP-1 Is Expressed at High Levels in MYC-Driven Human BL and Mouse DBLL 
Constitutive MYC-dependent activation of a large number of genes involved in a broad range of 
metabolic processes is responsible for the development of a variety of cancers [18,19]. Dosage-dependent 
effects  of  MYC  on  transformation  are  well  established [20–22],  and  studies  of  primary  human  
solid  tumors  have  shown  that  levels  of  ARF-BP1  expression  parallel  the  requirements  for  MYC  in 
proliferation [23]. To examine the potential contributions of ARF-BP1 to MYC-driven B cell neoplasms, 
we elected to study cell lines derived from human BL and mouse DBLL from λ-MYC TG mice.  
We  first  examined  the  levels  of  ARF-BP1  protein  expressed  by  BL  cell  lines  mutant  for  p53,  
EBV-transformed lymphoblastoid cells (LCL) lines with wild type (wt) p53, centroblastic (CB) and 
immunoblastic (IB) diffuse large B cell lymphomas (DLBCL), and the epithelial cell line, MCF 10A 
(Figure 1A). These studies showed that ARF-BP1 was expressed at higher levels by the BL cell lines 
than by the DLBCL lines and that MCF 10A cells were completely negative. In addition, it appeared 
that the levels of ARF-BP1 expression were higher in the BL lines bearing p53 mutations than in the Int. J. Mol. Sci. 2012, 13  6207 
 
 
LCL with a wt p53 gene. The relative protein levels of ARF and MYC to ARF-BP1 were nearly 
similar for each of the cell lines (Figure 1A). Parallel studies of mouse cell lines established from 
primary small B cell lymphomas (SBL), DBLL and splenic marginal zone lymphomas (MZL) showed 
that  ARF-BP1  was  expressed  at  uniquely  high  levels  in  MYC-driven  DBLL  (Figure  1B).  These 
findings indicate that ARF-BP1 is expressed at high levels in human and mouse B lineage lymphomas 
that express MYC at high levels. 
Figure  1.  (A)  Western  blot  analyses  of  ARF-BP1,  ARF,  and  MYC  in  human  Burkitt 
lymphoma (BL), EBV-transformed lymphoblastoid cells (LCL) and diffuse large B cell 
lymphomas (DLBCL). Mutational status of p53 in BL and LCL is indicated. MCF10A is a 
non-tumorigenic epithelial cell line as a negative control of ARF-BP1; (B) Western blot 
analyses of ARF-BP1 expressions in small B cell lymphomas (SBL-NFS216, NFS223 and 
NFS225), splenic marginal zone lymphomas (MZL-NFS204, NFS219 and NFS793) and  
λ-MYC diffuse high grade B cell lymphoblastic lymphomas (DBLL-SJ003-2, SJ003-4, and 
SJ003-5) from NFS.V
+ mice; (C) qRT-PCR analyses of transcript levels for ARF-BP1, 
ARF, p53, MYC, and CTCF in cell lines derived from different classes of B cell lineage 
neoplasms; (D) Western blot analyses of cell lysates from SBL, λ-MYC TG DBLL and 
MZL-derived  cell  lines  immunoprecipitated  with  ARF-BP1  antibody  and  blotted  with 
antibodies to ARF-BP1, ARF, p53, MYC and CTCF. 
 
We next proceeded to determine the patterns of expression for ARF-BP1 and its established partner 
and target proteins, ARF, p53 and Myc, by qRT-PCR analyses of transcript levels in a large panel of Int. J. Mol. Sci. 2012, 13  6208 
 
 
primary  B cell lineage  neoplasms from NFS.V
+ mice diagnosed as SBL, DLBCL of centroblastic 
(CBL)  and  immunoblastic  (IBL)  types,  DBLL,  and  MZL  (Figure  1C).  This  analysis  includes 
plasmacytoma (PCT) cell lines from BALB/c mice as NFS.V
+ PCT are infrequent. We also studied the 
same tumors for expression of CTCF, a versatile transcription factor previously shown to be involved 
in regulating the expression of ARF [24], p53 [25] and MYC [26]. The results showed that ARF-BP1 
and ARF were expressed at the highest levels in cells over-expressing MYC from the λ-MYC TG or 
due to activating chromosomal translocations in PCT. These results are consistent with earlier studies 
indicating that MYC contributes to the transcriptional activation of ARF. There is currently no basis for 
understanding why transcript levels of ARF-BP1 levels are elevated in cells with deregulated MYC, 
although earlier studies indicated that ARF-BP1 is not a direct transcriptional target of MYC [17]. 
Previous studies demonstrated protein-protein interactions between ARF-BP1 and ARF, MYC, p53 
and MCL1 with some of these interactions being context-dependent. For example, access of ARF-BP1 
to MCL1 is reported to occur only in cells exposed to DNA damaging agents [27]. Interestingly, CTCF 
has been shown in unpublished studies to interact physically with MYC [28]. These findings prompted 
us to ask if ARF-BP1 might interact with CTCF. We immunoprecipitated ARF-BP1 from SBL, DBLL 
and MZL-derived  cell lines, separated the proteins by SDS-PAGE, and blotted with antibodies to 
ARF-BP1, ARF, p53, MYC and CTCF (Figure 1D). Immunoprecipitation with normal IgG served as a 
negative control. The results showed that, as expected, ARF, p53 and MYC co-immunoprecipitated 
with ARF-BP1 from lysates of the DBLL cell line that expresses ARF-BP1 at high levels. Strikingly, a 
strong signal was also obtained for CTCF, identifying it as another component of this macromolecular 
complex. All four partner proteins were also brought down, but at lower levels, in precipitates from the 
SBL and MZL cell lines (Figure 1D). The IP controls including protein-A-agarose beda, IgG and 
antibody against beta-actin that does not bind with ARF-BP1, did not produce bands when blotted with 
antibodies against ARF, ARF-BP1, p53, MYC, and CTCF (data not shown). Further studies would be 
required to determine which proteins in this complex interact directly with the others and which are 
pulled down through indirect interactions. 
2.2. ARF-BP1 Binds to and Ubiquitylates CTCF 
Previous  studies  demonstrated  that  the  functional  activity  of  CTCF  is  modulated  by  
phosphorylation [29]. In addition, SUMOylation contributes to the repressive function of CTCF on the 
MYC P2 promoter [30] and poly-ADP ribosylation is reported to be important for CTCF-dependent 
chromatin insulation [31]. The finding that CTCF and ARF-BP1 associate in vivo under pathologic 
conditions suggested that CTCF might also be modified by ARF-BP1-dependent ubiquitylation. To 
investigate this possibility, we performed studies using full length CTCF or the central CTCF zinc 
finger (ZF) region and showed that both constructs pulled down ARF-BP1 (data not shown). 
Although previous studies had shown that CTCF was post-translationally modified by the small 
ubiquitin-like protein SUMO with the repressive polycomb protein, Pc2, acting as a SUMO E3 ligase, 
there  are  no  reports  of  CTCF  modification  by  ubiquitylation [30].  To  determine  if  CTCF  can  be 
ubiquitylated  in  vivo,  293  cells  were  co-transfected  with  FLAG-CTCF  and  HA-tagged  ubiquitin  
(HA-Ub) in the presence or absence of the proteasome inhibitor, MG132. The 293 cells were used 
rather than B cell lines because of technical limitations posed by efficient transfection of non-adherent Int. J. Mol. Sci. 2012, 13  6209 
 
 
cells. Cell lysates were precipitated with anti-FLAG. The precipitates were separated electrophoretically 
and  immunoblotted  with  anti-HA-tag  to  detect  ubiquitylated  CTCF.  The  results  of  these  studies 
(Figure 2A) demonstrated that CTCF when overexpressed could be modified by ubiquitin and that 
polyubiquitylated forms were readily detected in cells blocked for proteasomal degradation. 
Figure  2.  (A)  293  cells  were  co-transfected  with  FLAG-CTCF  and  with  HA-tagged 
ubiquitin (HA-Ub) in the presence or absence of MG132. Proteins were precipitated with 
anti-FLAG  and  blotted  with  anti-HA;  (B)  Overexpression  of  ARF-BP1  (3674-4374) 
enhances polyubiquitylation of CTCF. FLAG-tagged CTCF, HA-Ub, and an increasing 
amount  of  His-ARF-BP1  (3674-4374)  were  cotransfected  in  293T  cells  as  indicated. 
Proteins  were  precipitated  with  anti-FLAG  and  blotted  with  anti-HA;  (C)  ARF-BP-1 
ubiquitylates  endogenous  CTCF.  HA-Ub  and  His-ARF-BP1  (3674–4374)  were  
co-transfected into 293T cells in the presence of MG132 for 6 h and then harvested and 
lysed. Proteins were precipitated with anti-HA and blotted with anti-CTCF monoclonal 
antibody (D31H2); (D) CTCF levels are reduced in cells overexpressing ARF-BP1. HA-Ub 
and FLAG-ARF-BP1 (3674-4374) or vector alone was transfected in 293T cells. After 24 h, 
the cells were harvested and lysed. Proteins were precipitated with anti-FLAG and blotted 
with  anti-HA.  CTCF  levels  were  quantitated  by  densitometry;  (E)  Using  IP  and  
co-IP methods, MYC ubiquitylation was detected in BL cells (left), and ARF-BP1 binds 
MYC and induces its ubiquitylation (right). ARF-BP1-mediated ubiquitylation of MYC in 
BL is inhibited by ARF-BP1 siRNA (right). 
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To determine if ARF-BP1 was capable of acting as an E3 ligase for CTCF, we co-transfected 293 
cells with FLAG-CTCF, HA-Ub and increasing amounts of His-tagged C-terminal region of ARF-BP1 
that contains the HECT domain, aa 3674–4374. Protein lysates were precipitated with anti-FLAG and 
the precipitates separated electrophoretically and immunoblotted with anti-HA to detect ubiquitylated 
CTCF.  The  results  (Figure  2B)  showed  that  overexpression  of  ARF-BP1  resulted  in  enhanced 
polyubiquitylation  of  CTCF  in  a  dose-dependent  manner,  identifying  ARF-BP1  as  an  E3  ligase  
for CTCF. 
We then asked if ARF-BP1 might be active in ubiquitylating endogenous CTCF. 293 cells treated 
with  MG132  were  transfected  with  Ha-Ub  and  His-ARF-BP1  (3674–4374)  and  lysed  6  h  later.  
HA-Ub-modified proteins were immunoprecipitated with anti-HA mAb, and then analyzed for the 
extent of CTCF ubiquitylation by immunoblotting with a mAb to CTCF. These studies (Figure 2C) 
showed that endogenous CTCF was constitutively ubiquitylated and that the levels of modification 
were greatly increased in cells overexpressing ARF-BP1. 
Our  earlier  studies  suggested  that  when  CTCF  was  overexpressed,  ubiquitylation  directed  the 
protein  to  proteasomal  degradation.  To  determine  if  ubiquitylation  by  ARF-BP1  would  affect  the 
stability of endogenous  CTCF, 293 cells were transfected with empty vector or vector expressing  
His-tagged ARF-BP1 (3674–4374). The cells were harvested 24 h later and endogenous CTCF levels 
were determined by immunoblotting and quantified by densitometry using tubulin levels as a control  
(Figure 2D). The results showed that the levels of endogenous CTCF were reduced by nearly 50% in 
cells overexpressing ARF-BP1. We conclude that ARF-BP1 is an E3 ligase for endogenous CTCF and 
that polyubiquitylation of CTCF leads to its proteasomal degradation. 
2.3. ARF-BP1 Ubiquitylates MYC in B Lineage Cells 
Previous  studies  using  U2OS,  HeLa  and  293  cells  demonstrated  that  ARF-BP1  catalyzes  
K-63-linked  ubiquitylation  of  MYC  thereby  switching  MYC  from  a  repressive  to  an  activating  
state [23]. To determine if MYC is ubiquitylated by ARF-BP1 in B cell neoplasms, we first took 
advantage of the P493-6 human B cell line that is derived from an EBV-immortalized B cell line and 
carries  a  conditional  tetracycline-regulated  MYC [24].  Protein  extracts  from  cells  with  MYC  “on” 
(Myc+) and Myc “off” (Myc−) were precipitated with antibodies to its transcriptional partner protein, 
MAX, separated by SDS-PAGE and blotted with antibodies to ubiquitin or MYC (Figure 2E, left 
panel). The results revealed multiple bands reactive with the anti-Ub antibodies in the extracts from 
MYC “on” cells but not MYC “off” cells, demonstrating that MYC is highly ubiquitylated as in other 
cell types. To determine if ARF-BP1 was responsible for MYC ubiquitylation, we performed similar 
studies with MYC+ cells that had been treated with an ARF-BP1-specific or a control siRNA (Figure 2E, 
right panel). The results showed that, as previously established for other cell types [23], MYC ubiquitylation 
in B lineage cells was highly dependent on ARF-BP1. 
2.4. Inactivation of ARF-BP1 Stabilizes p53, Induces p53-Dependent Apoptosis, and Reduces Cell 
Proliferation in λ-MYC TG Cells 
We next examined the effects of changes in ARF-BP1 levels induced by suppressive siRNA on 
expression of p53, the p53 transcriptional targets, p21 and BAX, and on CTCF (Figure 3A). A DBLL Int. J. Mol. Sci. 2012, 13  6211 
 
 
cell line derived from a λ-MYC lymphoma that was treated with an ARF-BP1-specific siRNA had 
greatly increased levels of each of these proteins, consistent with studies performed with cells from 
other lineages [15,17]. The effects of ARF-BP1 suppression on CTCF were in keeping with our earlier 
studies indicating that ubiquitylation enhanced proteasomal degradation of the protein. Interestingly, 
the enhanced levels of p53 protein associated with ARF-BP1 knockdown were not associated with 
increased protein stability, suggesting important contributions from other degradative and presumably 
ARF-BP1-dependent mechanisms (Figure 3B). 
Figure 3. Effects of ARF-BP1 downregulation on expression of p53, p21, Bax and CTCF 
and cell cycle progression. (A) Protein extracts from DBLL cells with wt p53 transfected 
with an ARF-BP1-specific or a control siRNA were blotted with antibodies to the indicated 
proteins; (B) Quantitation of p53 protein levels in cells transfected with a control or an 
ARF-BP1-specific siRNA relative to levels of β-actin, indicated by ratios; (C) Cell cycle 
analysis of DBLL cells treated with a control siRNA or an ARF-BP1-specific siRNA by 
flow cytometry and quantitation of the frequencies of sub-G1 apoptotic cells and cells in 
G1, S or G2/M. 
 
The changes in expression of p53, p21 BAX and CTCF induced by siRNA to ARF-BP1 were 
reflected by changes in cell cycle regulation and apoptosis. As shown in Figure 3C, cells treated with 
the ARF-BP1-specific siRNA had reduced frequencies of cells in cycle and had greatly increased 
numbers of sub-G1 cells, indicative of an apoptotic population. 
3. Discussion 
The functions of the p53 tumor suppressor protein and the MYC oncogene are finely tuned through 
a  myriad  of  interactions  with  other  proteins.  These  interactions  can  lead  to  posttranslational Int. J. Mol. Sci. 2012, 13  6212 
 
 
modifications  that  regulate  protein  stability,  DNA  binding  or  promoter-specific  transcriptional 
activation or repression [14,23,32]. It is currently well accepted that ubiquitylation plays a major part 
in regulating the activities of both p53 and MYC and that this reflects the activities of a seemingly ever 
increasing number of different E3 ligases [25,32]. ARF-BP1 is unique among these E3 ligases in that it 
targets both p53 and MYC with profound effects on the development and growth of a variety of  
MYC-driven solid tumors [15]. 
Firstly,  the  results  presented  here  demonstrated  that  ARF-BP1  was  also  highly  expressed  in  
MYC-dependent  B  cell  lineage  neoplasms  of  both  humans  and  mice.  Interestingly,  the  mouse 
neoplasms that expressed ARF-BP1 at high levels derived from near opposite ends of the mature B cell 
developmental spectrum in mice including DBLL that derive from pre-germinal center (pre-GC) B 
cells to PCT, which originate from mature plasma cells. In humans, they also included BL and DLBCL 
of GC origin. 
Secondly, depletion of ARF-BP1 in a DBLL cell line resulted in inhibition of cell cycle progression 
and  increased  apoptosis.  These  results  paralleled  to  previous  studies  of  ARF-BP1  knockdowns  in 
MYC-dependent human tumor cell lines raising the possibility that ubiquitylation of MYC may be the 
defining function of ARF-BP1 in tumor survival and proliferation [15]. Importantly, ARF-BP1 was 
expressed in human tumors and LCL expressing either wt or mutant p53 supporting the suggestion  
that it could be a therapeutic target in a variety of MYC-dependent lymphomas or EBV-dependent 
lymphoproliferative disorders regardless of p53 status [17]. 
Thirdly, while previous studies had shown that ARF, ARF-BP1 and MYC could form a ternary 
complex [26], our analyses of DBLL cells demonstrated that ARF-BP1 could be part of an even larger 
multiprotein complex that also includes p53, MAX and CTCF. The presence of p53 and MAX in this 
complex can probably be understood as a consequence of p53 being a known target of ARF-BP1 and 
the partnership of MYC and MAX in MYC transcriptional activation promoted by ubiquitylation of 
MYC by ARF-BP1. 
The identification of CTCF as part of this complex is of particular interest for several reasons; the 
first is its contributions to regulated expression of other protein components of the complex (Figure 4). 
Binding of CTCF to the p53 promoter is reported to protect the gene from epigenetic silencing [33], 
while methylation-sensitive binding to sequences in the regulatory region is required for activation of 
the INK4A/ARF locus [34]. Secondly, binding of CTCF at the human MYC locus is required for gene 
expression  and  protection  from  methylation [35].  Finally,  ectopic  expression  of  CTCF  results  in 
profound  inhibition  of  cell  cycle  progression  [36,37],  phenotypes  we  found  to  be  associated  with 
depletion of ARF-BP1. 
The interactions of ARF-BP1and CTCF were shown to require the central 11 ZF DBD of CTCF 
and  the  C-terminal  region  of  ARF-BP1  that  contains  the  HECT  E3  ligase  domain.  Studies  using 
transfected CTCF showed that it was polyubiquitylated, the levels of ubiquitylation were increased 
following co-transfection with an ARF-BP1 expression vector and the effect of ubiquitylation was to 
direct modified CTCF to proteasomal degradation. Finally, we showed that polyubiquitylation was not 
dependent  on  overexpression  of  CTCF  and  the  levels  of  endogenous  CTCF  ubiquitylation  were 
increased in cells co-transfected with ARF-BP1. 
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Figure  4.  Features of  protein-protein interactions and transcriptional regulation of  genes 
involved governing cell proliferation and survival of MYC-driven B cell lineage neoplasms. 
Post-translational ubiquitylation (Ub) of p53 and CTCF by ARF-BP1 and p53 by MDM2 is 
inhibitory (red lines and bars), directing proteasomal degradation. Ubiquitylation of MYC by 
ARF-BP1  promotes  transcriptional  activity  of  MYC/MAX  heterodimers  (green  arrow). 
Binding of CTCF to the promoters of p53, ARF and MYC is permissive for transcription 
while  MYC  effects  transcriptional  activation  of  ARF  and  p53  activates  transcription  of 
MDM2 (blue arrows). ARF inhibits the activities of both ARF-BP1 and MDM2 (red bars). 
Previous studies also indicate that MYC can indirectly promote transcriptional activation  
of CTCF. 
 
Previous studies showed that CTCF interacts with a wide range of proteins that may approach 60 in 
number and include YY1, PARP1, NPM, UBF, cohesins, and RNAPII among others [32,38]. Although 
CTCF  was  previously  shown  to  be  modified  post-translationally  by  SUMOylation [30], 
phosphorylation [39] and poly(ADP) ribosylation [31], to our knowledge this is the first report that 
CTCF is modified by ubiquitylation. While the other modifications affect the functional activity of 
CTCF, they have not been reported to alter its stability. Currently, we do not know if ARF-BP1 is the 
only  E3  ligase  capable  of  modifying  CTCF,  the  nature  of  ubiquitylation,  or  if  ubiquitylation  is 
countered by the activity of deubiquitylating enzymes such as DUB1 [32]. It will be very important to 
determine the sub-cellular localization of the ARF-BP1-CTCF interaction. If it occurs in the nucleus, it 
may counteract SUMOylation. Since SUMOylated CTCF inhibits MYC promoters, ubiquitylation may 
result in transcriptional activation at these target sites. 
CTCF is a highly versatile protein that serves a wide variety of functions [40]. At present, it is 
unsure whether these functions might be affected by changes in CTCF levels along with cell cycle 
progression, stress or differentiation or by differences in subcellular localization of CTCF. 
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Ubiquitylation plays a key role in regulating the activity of multiple oncoproteins, including those 
of the MYC family. MYC is a short-lived protein that is degraded through the ubiquitin-proteasome 
pathway [41]. The F Box E3 ligase, FBW7, recognizes MYC phosphorylated at threonine 58 by GSK3, 
polyubiquitylates  MYC,  and  then  leads  its  degradation  by  the  26S  proteasome [42].  Inhibition  of 
GSK3 stabilizes MYC in lymphoma patients [43]. However, ubiquitylation of transcription factors 
does  not  necessarily  result  in  inhibition,  although  it  can  control  their  activity  independent  of 
proteasomal degradation [44]. It has been reported that the switch between transcriptional activation 
and repression by MYC is regulated by site-specific ubiquitylation [23]. SKP2 is another E3 ligase for 
MYC ubiquitylation, binding to a conserved sequence element in the amino-terminus [23]. This is 
thought to be essential for transformation and transcriptional regulation [4]. 
It has been shown that ARF-BP1 also functions as an E3 ubiquitin ligase for MYC and it regulates 
the switch between the activated and repressed state of the MYC protein. Inactivation of ARF-BP1 
repressed MYC ubiquitylation in λ-MYC cells that express a high level of activated MYC. Previous 
studies demonstrated that ARF-BP1 assembles Lys63-linked polyubiquitin chains on MYC and this 
modification  is  required  for  gene  activation  by  MYC,  allowing  the  interaction  of  MYC  with  the  
p300 coactivator [23]. Such K63-linked polyubiquitin chains do not target proteins for proteasomal 
degradation; instead they regulate the function of the modified protein. However, a recent report has 
shown that ARF-BP1 ubiquitylates MYCN through Lys48-mediated linkages and thereby targets it for 
destruction by the proteasome [8]. The induction of ARF by MYC resulting in inhibition of ARF-BP1 
may serve as a negative feedback loop to limit excessive MYC function. 
Recent  support  for  the  concept  that  ARF-BP1  is  critically  important  in  regulating  the  balance 
between pathways governing survival and death of B cell lineage lymphomas, in part through effects 
on p53, comes from studies of mice with a B cell-specific deficiency in ARF-BP1 [16]. Mutant B cells 
exhibited elevated expression of p53 and of p53 target genes in association with impaired development 
and homeostasis. Similar conclusions regarding ARF-BP1 control of p53 activity were drawn from 
studies of pancreatic B cells conditionally deficient in expression of ARF-BP1 [45]. 
As  summarized  in  Figure  4,  the  studies  presented  here  identify  a  previously  unrecognized 
component  of  an  interacting  network  of  proteins  that  control  proliferation  and  apoptosis  in  
MYC-driven B cell lineage lymphomas of mice and humans. To the well-documented interactions 
between ARF-BP1, MYC, p53 and MDM2, established from studies of a variety of solid tumors, we 
have now added the multifunction nuclear factor, CTCF, and showed that it is part of the scaffolding of 
a  multimolecular  complex.  The  effects  of CTCF  on the  transcription  of MYC, ARF  and p53  are 
certainly nucleoplasmic and the ARF-BP1-CTCF interactions are equally certain to be nuclear and 
directly chromatin-associated as there is little or no cytoplasmic CTCF and almost all CTCF appears to 
be tightly chromatin bound. It will be of interest to determine if all CTCF is equally accessible to  
ARF-BP1 as it is in nucleus during interphase, associates with the centrosome during mitosis and 
localizes to the midbody and reformed nuclei during telophase [29,31,32,38,40]. How ubiquitylation 
relates to other post-translational modifications will also be of considerable interest. Finally, it remains 
to  be  determined  if  the  sole  effect  of  ARF-BP1-mediated  ubiquitylation  on  CTCF  is  to  direct 
proteasomal degradation. 
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4. Experimental Section 
4.1. Mice and Cell Lines 
NFS.V
+ mice that develop a spectrum of B cell lineage neoplasms [16] and λ-MYC TG mice were 
described previously [12,46]. Tissues obtained at necropsy were used for tumor classification using 
established criteria [47], and for later preparation of RNA, DNA and protein extracts. Plasmacytoma 
(PCT) cell lines were a gift from Michael Potter (NCI, NIH, Bethesda, MD, USA). All animal studies 
were performed under NIAID IACUC approved protocol LIP6. 
Single cell suspensions prepared from spleen or lymph nodes of tumor bearing λ-MYC TG mice 
were cultured to develop cell lines. The cell lines were shown to be clonal based on Southern blot 
analyses of immunoglobulin heavy chain organization and were found to be phenotypically similar to 
normal splenic transitional B cells [48]. 
Human BL and EBV-transformed LCL cell lines were generously provided by G.W. Bornkamm [49] and 
M.D. Scharff (BL2). Human diffuse large B cell lymphoma (DLBCL) cell lines VAL and LY were a 
gift from R. Dalla-Favera. MCF 10A, and HEK 293 cell lines are from our laboratories. 
4.2. Protein extraction, Western Blotting, and Immunoprecipitation 
Nuclear and cytoplasmic protein fractions were extracted and western blotting was performed as 
previously  described [50].  For  immunoprecipitation  studies,  300  µg  of  protein  in  500  µL  of  2X 
immunoprecipitation buffer (2% Triton X-100, 300 mM NaCl, 20 mM Tris [pH 7.4], 2 mM EDTA,  
2 mM EGTA, pH 8.0, 0.4 mM sodium orthovanadate, 0.4 mM PMSF and 1.0% NP-40) and 400 µ L 
H2O were incubated with anti-ARF-BP1 or other antibodies on beads (NeoMarkers, Fremont, CA, 
USA),  according  to  the  manufacturer’s  instructions.  The  immune  complexes  were  collected  and 
analyzed by SDS-PAGE. 
4.3. RNA Isolation and Analysis by Quantitative RT-PCR (qRT-PCR) 
Total RNAs were isolated from tumor cells and used for qRT-PCR as described previously [50]. 
Primers designed using the Primer Express software (Applied Biosystems, Foster City, CA, USA). All 
samples were tested in triplicate. The comparative CT method was used for quantification of gene 
expression.  Statistical  analysis  was  performed  using  SDS  v2.1  software  (Applied  Biosystems) 
according to the manufacturer’s instructions. Gapdh was used as an endogenous reference. 
4.4. Ubiquitylation Assay 
For  detection  of  protein  ubiquitylation,  cells  were  washed  with  ice-cold  PBS  and  lysed  in  a  
NP40-containing buffer (50 mM Tris-HCl [pH 7.4], 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1 mM 
Na3VO4, 1% NP40, 0.02% NaN3, 1 mM PMSF, and protease inhibitor cocktail [Roche]) for 30 min on 
ice.  Extracted  proteins  were  pre-cleared  with  protein  G  agarose  beads  (Invitrogen)  followed  by 
incubation with 5 μg Ab coupled to protein G agarose beads overnight at 4 ° C. Beads were washed three 
times in 20 vol of ice-cold lysis buffer, resuspended in 1×  NuPAGE LDS sample buffer (Invitrogen) 
containing 50 nM DTT, and boiled for 5 min. Equal amounts of protein for each sample were separated Int. J. Mol. Sci. 2012, 13  6216 
 
 
on 3–8% Tris-Acetate gels (Invitrogen) and subsequently transferred to PVDF membranes (Invitrogen) 
in 1X NuPAGE transfer buffer (Invitrogen). After blocking with 5% skim milk for 1 h in PBS-T (0.1% 
Tween 20 in PBS), membranes were subsequently incubated with primary Abs and then with respective 
HRP-conjugated secondary Abs (Santa Cruz). Blots were developed with either SuperSignal West Pico 
or Dura (Pierce) and exposed to Biomax MR film (Kodak). 
The  antibodies  used  in  this  experiment  were  mouse  monoclonal  antibodies  specific  for  
Flag  (1:1000;  M2;  Sigma),  His  (1:500;  Invitrogen)  and  rat  monoclonal  antibody  specific  for  HA  
(1:1000; Roche). 
4.5. Cell Cycle Analysis 
The Click-iT
 EdU Flow Cytometry Assay Kit (Invitrogen) was used to analyze cell cycle, according 
to the manufacturer’s instructions. 
5. Conclusions 
Taken together, the present findings demonstrated that ARF-BP1 is an important determinant in 
MYC-driven lymphoid malignancies of mice and humans by virtue of its interactions with ARF, p53 
and MYC, as well as CTCF (Figure 4). ARF-BP1 can act to promote BL tumor development by:  
(1) inducing ubiquitylation and degradation of p53; (2) enhancing the transcriptional activity of MYC; 
and  (3)  by  direct  ubiquitylation  of  CTCF.  Down-regulation  of  ARF-BP1  could  be  an  important 
therapeutic target for MYC-driven B cell lineage neoplasms, especially for cases with p53 aberrations, 
by reducing transcriptional activation of MYC target genes. ARF-BP1 may thus provide a potential 
target for developing improved treatments for human BL. 
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